Although new treatments, such as TNF-alpha antagonists, are increasingly used, the mortality rate among patients with neurosarcoidosis remains 5% and about one third does not have a substantial clinical improvement on treatment. The gene discussed is TNF; the disease is neurosarcoidosis.